Company: WENNU
Filing Date: 2025-04-30
Form Type: S-1
Source: 0001213900-25-037753
Chunk: 14

Company: WEN Acquisition Corp
Filing Date: 2025-04-30
Form: S-1
Chunk 14
---
 in common stock, at a price of $10.00 per share. In February 2023, Paya Inc, was purchased by Nuvei for $9.75 per share. • FinTech Acquisition Corp. IV: Mr. Patel served as an advisor to FinTech Acquisition Corp. IV (“FinTech IV”). FinTech IV completed its initial public offering of $239.0 million in September 2020, and consummated its initial business combination with PWP Holdings LP (NASDAQ: PWP) in June 2021. None of FinTech IV’s public shares were redeemed in connection with the business combination. PIPE investors committed to purchase an aggregate of $125.0million in common stock, at a price of $10.00 per share. PWP’s closing price on April25, 2025 was $16.89 per share. • FTAC Olympus Acquisition Corp.: Ryan Gilbert, one of our advisors, served as Chief Executive Officer, President and a director, and Mr. Patel served as Chief Operating Officer, to FTAC Olympus Acquisition Corp. (NASDAQ: FTOC) (“FTOC”). FTOC, after its initial public offering of $755 million in August 2020, consummated its initial business combination with Payoneer Global Inc. (NASDAQ: PAYO) in June 2021. In connection with the business combination, approximately 23.9% of FTAC Olympus’ public shares were redeemed. PIPE investors committed to purchase an aggregate of $300.0million in common stock, at a price of $10.00 per share. Payoneer’s closing price on April25, 2025 was $6.97 per share. • Locust Walk Acquisition Corp.: Mr. Gilbert and Mr. Patel served as advisors to Locust Walk Acquisition Corp. (NASDAQ: LWAC) which merged with eFFECTOR therapeutics (NASDAQ: EFTR) in August 2021 (in which approximately 97.0% of LWAC’s public shares were redeemed). PIPE investors committed to purchase an aggregate of $60.7million in common stock, at a price of $10.00 per share. eFFECTOR therapeutics effected a wind down in June 2024 and no longer trades on an exchange. • Phoenix Biotech Acquisition Corp.: Mr.Gilbert and Mr.Patel served as advisors to Phoenix Biotech Acquisition Corp. (NASDAQ: PBAX), which merged with CERo Therapeutics (Nasdaq: CERO) in